The list below displays information about clinical trials sponsored by Ipsen.
Only interventional studies that have started within the last 20 years and completed within the 2 last years will be displayed.
The study results will be available on ClinicalTrials.gov from 12 months after the end of the study.
Last Data Refreshed @ 15-May-2025 16:08:09 UTC
Filters
Condition
Status
Phase
Country
Showing : 1 – 5 of 105 clinical trials
Upper Limb Spasticity
Dysport
Australia
Not Yet Recruiting
Dummy study Ipsen.com 2025 with only EUDRACT
This is a test
1. line break
2. line break
Upper Limb Spasticity
Dysport
Austria
Not Yet Recruiting
Dummy study Ipsen.com 2025 with only EUCT
This is a test
1. line break
2. line break
Fibrodysplasia Ossificans Progressiva (FOP)
Sohonos
United States of America (the)
United Kingdom of Great Britain and Northern Ireland (the)
Brazil
France
Canada
Australia
Argentina
Italy
Spain
Sweden
Not Yet Recruiting
A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ?14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies.
The main objective of this study is to further evaluate the safety and efficacy of palovarotene in adult and paediatric participants with FOP. The aim of the study is also to ensure treatment continuity to participants who have completed one of the parent studies (Study PVO-1A-301, Study PVO-1A-202 and Study PVO-1A-204) and who, in the investigator’s judgement, may benefit from palovarotene therapy.
Indication Study X1
elafibranor
United States of America (the)
United Kingdom of Great Britain and Northern Ireland (the)
Italy
France
Gabon
Not Yet Recruiting
Public Title Study X1
Brief Summary study X1
Indication Study X1
elafibranor
United Kingdom of Great Britain and Northern Ireland (the)
United States of America (the)
Gabon
France
Italy
Not Yet Recruiting
Public Title Study X1
Brief Summary study X1